Developing better treatments in hepatocellular carcinoma
暂无分享,去创建一个
[1] H. Arioka,et al. A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma , 2011, Cancer Chemotherapy and Pharmacology.
[2] G. Abou-Alfa,et al. Advanced hepatocellular carcinoma: which staging systems best predict prognosis? , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] J. Bruix,et al. Sorafenib (SOR) or placebo (PL) in combination with transarterial chemoembolization (TACE) for intermediate-stage hepatocellular carcinoma (SPACE). , 2010 .
[4] G. Bodoky,et al. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). , 2010, The oncologist.
[5] A. Cheng,et al. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma , 2010, British Journal of Cancer.
[6] H. Huynh,et al. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). , 2010, Journal of hepatology.
[7] R. Finn,et al. An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC). , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] C. Bartolozzi,et al. A phase II (PhII) trial of sorafenib (S) in combination with 5-fluorouracil (5FU) continuous infusion (c.i.) in patients (pts) with advanced hepatocellular carcinoma (HCC): Preliminary data. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Ruey-min Lee,et al. A phase II study of AZD6244 in advanced or metastatic hepatocellular carcinoma. , 2016, Journal of Clinical Oncology.
[10] A. Zhu. Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)? , 2009, BMC medicine.
[11] E. Raymond,et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. , 2009, The Lancet. Oncology.
[12] F. Heindryckx,et al. Experimental mouse models for hepatocellular carcinoma research , 2009, International journal of experimental pathology.
[13] D. Esseltine,et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] R. Shoemaker,et al. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition , 2009, Molecular Cancer Therapeutics.
[15] Marek Ancukiewicz,et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] E. Van Cutsem,et al. Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Y. Shao,et al. A phase II study of sorafenib in combination with tegafur/uracil (UFT) for Asian patients with advanced hepatocellular carcinoma (HCC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Jeffrey S. Morris,et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Yun Yen,et al. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer , 2009, Cancer Chemotherapy and Pharmacology.
[20] Yoon-Koo Kang,et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.
[21] H. Hurwitz,et al. Early evidence of tolerability and clinical activity from a phase I study of TRC105 (anti-CD105 antibody) in patients with advanced refractory cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] S. Paggi,et al. Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .
[23] Derek Y. Chiang,et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. , 2008, Gastroenterology.
[24] Kenji Ikeda,et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. , 2008, The New England journal of medicine.
[25] P. Tartter,et al. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer? , 2008, American journal of surgery.
[26] P. Pollock,et al. Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma , 2008, Clinical Cancer Research.
[27] Lori Minasian,et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Gabriele Bergers,et al. Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.
[29] J. Llovet,et al. Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps , 2008, Current opinion in oncology.
[30] S. Rafii,et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] M. Hebbar,et al. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma , 2008, Cancer.
[32] B. Daniele,et al. Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma , 2008 .
[33] R. Goldberg,et al. Phase II study of oxaliplatin, capecitabine, and cetuximab in advanced hepatocellular carcinoma , 2008 .
[34] J. Trotter,et al. Sirolimus‐based immunosuppression following liver transplantation for hepatocellular carcinoma , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[35] W. Scheithauer,et al. Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] T. Sauerbruch,et al. Accelerated orthotopic hepatocellular carcinomas growth is linked to increased expression of pro‐angiogenic and prometastatic factors in murine liver fibrosis , 2008, Liver international : official journal of the International Association for the Study of the Liver.
[37] F. Farinati,et al. Transcatheter Arterial Chemoembolization (TACE) in Hepatocellular Carcinoma (HCC): The Role of Angiogenesis and Invasiveness , 2008, The American Journal of Gastroenterology.
[38] G. Abou-Alfa,et al. Current management of advanced hepatocellular carcinoma. , 2008, Gastrointestinal cancer research : GCR.
[39] Riccardo Lencioni,et al. Design and endpoints of clinical trials in hepatocellular carcinoma. , 2008, Journal of the National Cancer Institute.
[40] Xin Wei Wang,et al. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. , 2007, Cancer research.
[41] Jeffrey S. Morris,et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma , 2007, Cancer.
[42] G. Pond,et al. Phase I Targeted Combination Trial of Sorafenib and Erlotinib in Patients with Advanced Solid Tumors , 2007, Clinical Cancer Research.
[43] Jeffrey W. Clark,et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma , 2007, Cancer.
[44] C. Porta,et al. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] J. Pignon,et al. Bevacizumab in patients (pts) with advanced hepatocellular carcinoma (HCC): Preliminary results of a phase II study with circulating endothelial cell (CEC) monitoring , 2007 .
[46] M. Rosen,et al. Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): A phase II study , 2007 .
[47] M. Manns,et al. A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: Final results , 2007 .
[48] G. Melillo. Targeting hypoxia cell signaling for cancer therapy , 2007, Cancer and Metastasis Reviews.
[49] T. de Baère,et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC) , 2007, Cancer.
[50] J. Zucman‐Rossi,et al. Genetics of hepatocellular tumors , 2006, Oncogene.
[51] A. Benson,et al. Gefitinib in advanced unresectable hepatocellular carcinoma: Results from the Eastern Cooperative Oncology Group's Study E1203. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] Alona Muzikansky,et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] Alessandro Vitale,et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. , 2006, Journal of hepatology.
[54] B. Goh,et al. Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinoma , 2006, Pharmacogenetics and genomics.
[55] G. D’Amico,et al. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. , 2006, Journal of hepatology.
[56] Wei Wang,et al. Correlation between CD105 expression and postoperative recurrence and metastasis of hepatocellular carcinoma , 2006, BMC Cancer.
[57] W. Lau,et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. , 2005, Journal of the National Cancer Institute.
[58] P. Philip,et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] E. Raymond,et al. mTOR-targeted therapy of cancer with rapamycin derivatives. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[60] J. Marrero,et al. Prognosis of hepatocellular carcinoma: Comparison of 7 staging systems in an American cohort , 2005, Hepatology.
[61] R. Lucito,et al. Generation and analysis of genetically defined liver carcinomas derived from bipotential liver progenitors. , 2005, Cold Spring Harbor symposia on quantitative biology.
[62] R. Wilson,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[63] S. Thorgeirsson,et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling , 2004, Hepatology.
[64] Wen‐Hsiung Chang,et al. Salvage therapy for hepatocellular carcinoma with thalidomide. , 2004, World journal of gastroenterology.
[65] Y. Pommier,et al. Topoisomerase I-Mediated Inhibition of Hypoxia-Inducible Factor 1 , 2004, Cancer Research.
[66] D. Fukumura,et al. Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[67] T. T. Nguyen,et al. Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: Its role in tumor progression and apoptosis , 2003, BMC gastroenterology.
[68] J. Bruix,et al. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival , 2003, Hepatology.
[69] Pietro Andreone,et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. , 2002, Radiology.
[70] L. Staudt,et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[71] Ramon Planas,et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial , 2002, The Lancet.
[72] John Wong,et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma , 2002, Hepatology.
[73] S. Fan,et al. Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[74] Jacques Ferlay,et al. Estimating the world cancer burden: Globocan 2000 , 2001, International journal of cancer.
[75] W. Lau,et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[76] K. Tanikawa,et al. Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. , 1998, Human pathology.
[77] I. Su,et al. Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: an immunohistochemical study. , 1997, Human pathology.
[78] G. Dusheiko,et al. Management of hepatocellular carcinoma. , 1992, Journal of hepatology.